Dalrada Health and Vivera Pharmaceuticals AnnounceNew Diagnostic Laboratory Joint Venture
Pala Diagnostics, a CLIA-certified state-of-the-art diagnostic laboratory will provide laboratory mobile concierge service for businesses, conventions, hospitality, and schools to facilitate safer back-to-work and back-to-school protocols.
To address the ongoing demand for COVID-19 testing and to catalyze safe return of the workforce, Dalrada Corporation (OTCQB: DFCO, “Dalrada”) is excited to announce that its subsidiary, Dalrada Health, entered into a joint venture partnership with Vivera Pharmaceutical, Inc. (“Vivera”) to form Pala Diagnostics, LLC (“Pala Diagnostics”). The expanded national capabilities of Mission Viejo, California-based Pala Diagnostics include full on-site testing services for high-volume settings, rapid results within 24 hours for PCR testing, and a range of life science testing including SARS-CoV-2.
ointly, Dalrada Health & Vivera will collaborate to ensure businesses continuity and longevity. Initially, Pala Diagnostics will offer point-of-care, EUA approved, rapid antigen testing and lab-based PCR testing for COVID-19.
For this joint venture, Dalrada Health identified regulatory, quality assurance, and compliance requirements and certifications needed to address high-volume operations. Dalrada Health streamlined efficiencies by implementing the policies, procedures, and processes then placed industry expert personnel to accelerate the establishment of Pala Diagnostics.
Brian Bonar, Chairman and CEO of Dalrada states, “Routine COVID-19 testing is an ongoing requirement for some industries including universities, businesses, airlines, and public venues. As people return to school, work, traveling, and gathering, Pala Diagnostics’ mobile concierge and certified laboratory services play a vital role.”
Vivera brings to the Pala Diagnostics joint venture its current operations including its extensive network of health care providers and end customers across multiple industries. Vivera is vertically integrated with technology and distribution for its pharmaceutical, medical device, advanced diagnostics, and medical technologies products. Vivera has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug-delivery system for the pharmaceutical use of therapeutic compounds.
Paul Edalat, Chairman and CEO of Vivera states, “This joint venture between Dalrada Health and Vivera expands operational capabilities for Pala Diagnostics. Vivera has, since the beginning of the pandemic, sought to bring the best of COVID-19 testing to patients and providers. As schools and businesses begin to reopen on a full-time basis, we look forward to providing testing services to ensure safer communities.”
As strain variants emerge from the ongoing world health crisis, accurate testing remains a vital service. Pala Diagnostics puts patients first by focusing on access to testing for all. In addition to addressing demands from current SARS-CoV-2 testing, Pala Diagnostics plans additional offerings in the future.
About Vivera Pharmaceuticals, Inc.
Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and owns its own patents on ZICOH®, a controlled, medication dispensing device. In addition to its pharmaceutical, neurosciences, medical device, and medical technology divisions, the Company provides testing solutions through its advanced diagnostics division. Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.
About Dalrada Health
A wholly-owned subsidiary of Dalrada Corporation, Dalrada Health is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit www.dalradahealth.com
About Dalrada (DFCO)
With perseverance, valor, dedication, and vision, Dalrada Corporation is dedicated to tackling worldwide challenges of today and tomorrow.
Dalrada is a global company that operates under the tenet of creating impactful innovations that matter for the world. The Company works continually to produce disruptive solutions that bridge the gap of accessibility and accelerate positive change for current and future generations.
Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. Each of Dalrada’s subsidiaries actively produces affordable and accessible world-class solutions to global problems. For more information, please visit www.dalrada.com
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.